Technology [ 9/13 ] | Software - Application [ 87/164 ]
NASDAQ | Common Stock
Materialise NV provides additive manufacturing and medical software, and 3D printing services in the Americas, Europe and Africa, and the Asia-Pacific.
The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing.
The Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers and of 3D printing operations.
Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners.
This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, Website, and third party distributors.
The Materialise Medical segment provides medical software that allows medical-image based analysis, planning, and engineering, as well as patient-specific design and printing of surgical devices and implants.
It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, Website, and picture archiving and communication system.
The Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to industrial and commercial customers.
The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Smith & Nephew Inc.; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 25, 24 | 0.06 Increased by 0.00% | 0.03 Increased by +100.00% |
| Feb 21, 24 | -0.01 Increased by +87.50% | 0.06 Decreased by -116.67% |
| Oct 26, 23 | 0.07 Increased by +250.00% | 0.01 Increased by +600.00% |
| Jul 26, 23 | -0.01 Decreased by -150.00% | 0.05 Decreased by -120.00% |
| Apr 27, 23 | 0.06 Increased by +2.30 K% | -0.07 Increased by +185.71% |
| Feb 14, 23 | -0.08 Decreased by -200.00% | 0.02 Decreased by -500.00% |
| Oct 27, 22 | 0.02 Decreased by -86.67% | 0.01 Increased by +166.67% |
| Jul 28, 22 | 0.02 Decreased by -66.67% | 0.02 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 63.62 M Increased by +1.46% | -515.43 K Increased by +88.77% | Decreased by -0.81% Increased by +88.93% |
| Dec 31, 23 | 63.62 M Increased by +1.46% | -515.43 K Increased by +88.77% | Decreased by -0.81% Increased by +88.93% |
| Sep 30, 23 | 60.13 M Increased by +3.16% | 4.02 M Increased by +182.69% | Increased by +6.68% Increased by +174.02% |
| Jun 30, 23 | 64.81 M Increased by +11.61% | -488.00 K Decreased by -154.04% | Decreased by -0.75% Decreased by -148.42% |
| Mar 31, 23 | 62.70 M Increased by +10.03% | -4.59 M Decreased by -196.20% | Decreased by -7.32% Decreased by -187.44% |
| Dec 31, 22 | 62.70 M Increased by +10.03% | -4.59 M Decreased by -196.20% | Decreased by -7.32% Decreased by -187.44% |
| Sep 30, 22 | 58.29 M Increased by +11.67% | 1.42 M Decreased by -83.58% | Increased by +2.44% Decreased by -85.30% |
| Jun 30, 22 | 58.07 M Increased by +14.51% | 903.00 K Decreased by -73.77% | Increased by +1.56% Decreased by -77.10% |